News

Alkem Laboratories announced that the 52th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Alkem Laboratories announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting Rs 350. Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience. The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise. In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.

Net profit of Alkem Laboratories declined 22.69% to Rs 236.46 crore in the quarter ended March 2026 as against Rs 305.86 crore during the previous quarter ended March 2025. Sales rose 14.62% to Rs 3603.32 crore in the quarter ended March 2026 as against Rs 3143.75 crore during the previous quarter ended March 2025.For the full year,net profit rose 6.30% to Rs 2301.80 crore in the year ended March 2026 as against Rs 2165.48 crore during the previous year ended March 2025. Sales rose 13.48% to Rs 14712.27 crore in the year ended March 2026 as against Rs 12964.52 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3603.323143.75 15 14712.2712964.52 13 OPM %14.3612.45 -20.4319.38 - PBDT663.58508.83 30 3427.782884.19 19 PBT557.82396.34 41 3045.722527.03 21 NP236.46305.86 -23 2301.802165.48 6 Powered by Capital Market - Live News

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 28 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 28 May 2026.